Critical Contrast: Roivant Sciences (NASDAQ:ROIV) versus Relief Therapeutics (OTCMKTS:RLFTF)

Roivant Sciences (NASDAQ:ROIV) and Relief Therapeutics (OTCMKTS:RLFTF) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Analyst Ratings

This is a summary of current recommendations and price targets for Roivant Sciences and Relief Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	0	1	9	0	2.90
Relief Therapeutics	0	0	0	0	N/A

Roivant Sciences currently has a consensus target price of $16.50, suggesting a potential upside of 56.55%. Given Roivant Sciences’ higher probable upside, equities research analysts plainly believe Roivant Sciences is more favorable than Relief Therapeutics.

Earnings & Valuation

This table compares Roivant Sciences and Relief Therapeutics’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$123.24 million	68.92	-$1.01 billion	$5.20	2.03
Relief Therapeutics	N/A	N/A	N/A	N/A	N/A

Relief Therapeutics has lower revenue, but higher earnings than Roivant Sciences.

Insider and Institutional Ownership

64.8% of Roivant Sciences shares are held by institutional investors. 4.6% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Roivant Sciences and Relief Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	3,624.14%	-33.38%	-26.06%
Relief Therapeutics	N/A	N/A	N/A

Summary

Roivant Sciences beats Relief Therapeutics on 6 of the 8 factors compared between the two stocks.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

About Relief Therapeutics

Relief Therapeutics Holding AG, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of metabolic, dermatological, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting. It develops RLF-100, a synthetic form of vasoactive intestinal peptide (VIP) for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19, nonCOVID-19-related ARDS, pulmonary sarcoidosis, checkpoint inhibitor-induced pneumonitis, and chronic berylliosis. The company also develops RLF-TD011, a hypochlorous acid topical sprayable solution to treat wound colonization, reduce local inflammation, alleviate symptoms, and hasten wound healing in epidermolysis bullosa. In addition, it develops OLPRUVA, a sodium phenylbutyrate for the treatment of various inborn errors of metabolism, urea cycle disorders, and maple syrup urine disease; APR-OD32, which is in phase 1 for the treatment of patients with phenylketonuria. Relief Therapeutics Holding AG was founded in 2013 and is based in Geneva, Switzerland.